Genprex (GNPX) Stock Price & Analysis Today

GNPX

(NASDAQ)

Genprex, Inc.

$0.79-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

Genprex Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$0.76 - $0.81

52-Week High$55.00

52-Week Low$0.81

Open$0.80

Volume185.94K

Average Volume (3M)981.49K

Market Cap774.45K

Shares Outstanding932.73K

Price to Book (P/B)0.10

EV/EBITDA0.45

50-Day MA$1.46

200-Day MA$5.29

52-Week Change-93.87%

Annual Dividend$0.00

Dividend Yield0.00%

Day's Range$0.76 - $0.81

52-Week High$55.00

52-Week Low$0.81

Open$0.80

Volume185.94K

Average Volume (3M)981.49K

Market Cap774.45K

Shares Outstanding932.73K

Price to Book (P/B)0.10

EV/EBITDA0.45

50-Day MA$1.46

200-Day MA$5.29

52-Week Change-93.87%

Annual Dividend$0.00

Dividend Yield0.00%

About Genprex

Company overview, fundamentals, and corporate profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation.The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive.The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy.Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Frequently Asked Questions About Genprex

What is the current stock price for GNPX?

As of the latest trading session, GNPX stock trades at $0.79. The 52-week range is $0.81–$55.00, with a day range of $0.76–$0.81.

What is the P/E ratio for GNPX?

The P/E ratio (Price-to-Earnings) for GNPX is shown in the Key Statistics section. This valuation metric helps compare Genprex, Inc. to industry peers.

Does GNPX pay dividends?

Genprex does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for GNPX?

Analyst ratings and recommendations for GNPX are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of GNPX?

Genprex's market capitalization is $734,991.24, classifying it as a micro-cap company. Genprex operates in the Healthcare sector within the Biotechnology industry.

Genprex (GNPX) Stock Price & Financial Analysis

Genprex Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About Genprex